Antioxidant strategies for Alzheimer's disease
- 1 May 2002
- journal article
- review article
- Published by Cambridge University Press (CUP) in Proceedings of the Nutrition Society
- Vol. 61 (2), 191-202
- https://doi.org/10.1079/pns2002146
Abstract
Oxidative damage is present within the brains of patients with Alzheimer's disease (AD), and is observed within every class of biomolecule, including nucleic acids, proteins, lipids and carbohydrates. Oxidative injury may develop secondary to excessive oxidative stress resulting from beta-amyloid-induced free radicals, mitochondrial abnormalities, inadequate energy supply, inflammation or altered antioxidant defences. Treatment with antioxidants is a promising approach for slowing disease progression to the extent that oxidative damage may be responsible for the cognitive and functional decline observed in AD. Although not a uniformly consistent observation, a number of epidemiological studies have found a link between antioxidant intake and a reduced incidence of dementia, AD and cognitive decline in elderly populations. In AD clinical trials molecules with antioxidant properties such as vitamin E and Ginkgo biloba extract have shown modest benefit. A clinical trial with vitamin E is currently ongoing to determine if it can delay progression to AD in individuals with mild cognitive impairment. Combinations of antioxidants might be of even greater potential benefit for AD, especially if the agents worked in different cellular compartments or had complementary activity (e.g. vitamins E, C and ubiquinone). Naturally-occurring compounds with antioxidant capacity are available and widely marketed (e.g. vitamin C, ubiquinone, lipoic acid, beta-carotene, creatine, melatonin, curcumin) and synthetic compounds are under development by industry. Nevertheless, the clinical value of these agents for AD prevention and treatment is ambiguous, and will remain so until properly designed human trials have been performed.Keywords
This publication has 98 references indexed in Scilit:
- Oxidative stress in Alzheimer’s diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2000
- Protective effects of huperzine A on β-amyloid25–35 induced oxidative injury in rat pheochromocytoma cellsNeuroscience Letters, 2000
- Serum levels of coenzyme Q 10 in patients with Alzheimer's diseaseJournal of Neural Transmission, 2000
- Vinpocetine attenuates the metabolic dysfunction induced by amyloid β-peptides in PC12 cellsFree Radical Research, 2000
- Cerebrospinal fluid levels of selenium in patients with Alzheimer's diseaseJournal of Neural Transmission, 1999
- Cerebrospinal fluid levels of transition metals in patients with Alzheimer's diseaseJournal of Neural Transmission, 1998
- Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's diseaseJournal of Neural Transmission, 1997
- Actions of Neurotoxic β‐Amyloid on Calcium Homeostasis and Viability of PC12 Cells Are Blocked by Antioxidants but Not by Calcium Channel AntagonistsJournal of Neurochemistry, 1996
- Oxidative damage in Alzheimer'sNature, 1996
- Vitamin E protects nerve cells from amyloid βprotein toxicityBiochemical and Biophysical Research Communications, 1992